Alvotech
No SEC Form 4 filings for $ALVO in the last 30 days.
Alvotech founder Róbert Wessman, 56, told Business Matters he may quit Britain, citing inheritance tax, capital gains tax and political instability that he says deter mobile wealth. He referenced Labour’s proposed “wealth tax” (costed by allies at ~£12bn/yr). Alvotech, Nasdaq-listed, invested $2bn since 2013; it reported $593m revenue in 2025 and guides $650m–$700m for 2026.
Alvotech (NASDAQ: ALVO) reported Q1 2026 revenue of $105.9 million and adjusted EBITDA of $24.4 million, impacted by production slowdowns from facility improvements, down from $132.8 million year-ago. Despite the quarterly dip, the company reaffirmed its 2026 revenue guidance of $650–700 million and adjusted EBITDA of $180–220 million. Alvotech also announced a strategic manufacturing agreement with FUJIFILM Biotechnologies to establish a U.S.-based second source of commercial supply and progressed with EMA marketing applications for AVT16 and AVT80.
UBS Group has reduced its price target for Alvotech (NASDAQ:ALVO) from $10.00 to $6.00 but maintained a "buy" rating, indicating a potential upside of 95.12%. Despite missing EPS estimates in the most recent quarter, Alvotech exceeded revenue forecasts, and the stock currently has a consensus "Hold" rating from analysts with a target price of $7.60. Shares are trading near their 52-week low, with institutional involvement including new stakes and increased holdings.
